SynAbs is proud to appoint LuBioSience as its new distributor for Switzerland. LuBioScience has a seasoned team and expertise in selling biochemicals, including the specific monoclonal antibodies of SynAbs, in particular the anti-species which should be welcomed by the Swits Biopharma R&D and IVD sector.
Roland Schärli - CEO LuBioScience GmbH
Phone: +41 41 417 02 80 - Fax: +41 41 417 02 89
Monoclonal antibodies development has been limited for a long time to only two species : mice and rats. However, the immune systems of mice and rats are not the most suitable in terms of humoral response to certain antigens, such as human antigens like glucagon. Indeed, the protein sequence of glucagon is the same in mice, rats and human (fig. 1). Small not immunogenic antigens, such as antibiotics or toxins, generally failed to trigger an immune response in such species. This is why some companies have developed fusion cell lines to
generate monoclonal antibodies in rabbit (Abcam-Epitomics) or in sheep (Bioventix). However, these two tools are not totally satisfactory whether in terms of cost, stability or productivity.
SynAbs has therefore opted to develop its own myeloma cell line to manufacture guinea pig monoclonal antibodies and offer more efficient investigation tools for researchers.
SynAbs proposes a catalog of more than 100 rat and mice monoclonal antibodies.
SynAbs maximizes the success rate and the quality of the mAbs generated in rats and mice. >> more about our technology
SynAbs is a dedicated Monoclonal Antibody Manufacturing Center.
>> read more about our team
31 July - 4 August
31 Oct. - 4 November
Philadelphia, USA, AACC
Stockholm, Sweden, Nordic Life Sciences
Paris, France, The European Diagnostic Matchmaking Event
Ghent, Belgium, Immunity for Health
Köln, Germany, Bioeurope fall
Düsseldorf, Germany, Medica 2016
Louvain-la-Neuve, Belgium, Biowin Day